| Literature DB >> 25933135 |
Marianne R F Bosscher1, Barbara L van Leeuwen1, Harald J Hoekstra1.
Abstract
OBJECTIVES: For some oncologic emergencies, surgical interventions are necessary for dissolution or temporary relieve. In the absence of guidelines, the most optimal method for decision making would be in a multidisciplinary cancer conference (MCC). In an acute setting, the opportunity for multidisciplinary discussion is often not available. In this study, the management and short term outcome of patients after surgical oncologic emergency consultation was analyzed.Entities:
Mesh:
Year: 2015 PMID: 25933135 PMCID: PMC4416749 DOI: 10.1371/journal.pone.0124641
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline characteristics of cancer patients who experienced surgical oncologic emergencies.
| Total n = 207 | |
|---|---|
|
| 101 (48.8) |
|
| 106 (51.2) |
|
| 64 (19–92 |
|
| |
| 0 | 57 (27.5) |
| 1 | 85 (41.1) |
| 2 | 47 (22.7) |
| 3 | 14 (6.8) |
| 4 | 4 (1.9) |
|
| |
| 1 | 22 (10.6) |
| 2 | 136 (5.7) |
| 3 | 49 (23.7) |
|
| |
| Day | 126 (60.9) |
| Evening | 24 (11.6) |
| Night | 11 (5.3) |
| Weekend day | 26 (12.6) |
| Weekend evening/night | 20 (9.7) |
|
| |
| Emergency Room | 147 (71.0) |
| In-hospital consultation | 35 (16.9) |
| Outpatient clinic | 19 (9.2) |
| Transfer from other hospital | 6 (2.9) |
|
| |
| Colorectal carcinoma | 54 (26.1) |
| Hepatobiliary | 18 (8.7) |
| Breast cancer | 14 (6.8) |
| Soft tissue sarcoma/GIST | 14 (6.8) |
| Neuroendocrine tumor | 13 (6.3) |
| Melanoma | 11 (5.3) |
| Cervix carcinoma | 8 (3.9) |
| Hematologic malignancy | 8 (3.9) |
| Esophageal carcinoma | 7 (3.4) |
| Non-melanoma skin cancer | 6 (2.9) |
| Lung carcinoma | 4 (1.9) |
| Prostate carcinoma | 3 (1.4) |
| Ovarian carcinoma | 3 (1.4) |
| Gastric carcinoma | 2 (1.0) |
| Other | 7 (3.4) |
| Unknown | 14 (6.8) |
| No cancer | 21 (10.1) |
|
| |
| No | 174 (84.1) |
| Yes | 33 (15.9) |
|
| |
| No cancer diagnosis before consultation | 21 (10.1) |
| <30 days | 26 (12.6) |
| 30 days—6 months | 56 (27.1) |
| 6 months—1 year | 20 (9.7) |
| 1–2 years | 13 (6.3) |
| 2–5 years | 41 (19.8) |
| > 5 years | 30 (14.5) |
|
| |
| |
|
| |
|
| Diagnostic stage | 32 (15.5) |
| Receiving treatment with curative intent | 49 (23.7) |
| Palliative stage | 48 (23.2) |
|
|
|
| < 30 days | 19 (9.2) |
| 30 days—6 months | 10 (4.8) |
| 6 months—1 year | 7 (3.4) |
| 1–2 years | 6 (2.9) |
| 2–5 years | 6 (2.9) |
| > 5 years | 9 (4.3) |
|
| 66 (31.9) |
|
| 72 (34.8) |
|
| 126 (60.9) |
|
| |
| Continuously | 24 (11.6) |
| < 30 days | 62 (30.0) |
| 30 days—6 months | 32 (15.5) |
| 6 months—1 year | 9 (4.3) |
| 1–2 years | 15 (7.2) |
| 2–5 years | 5 (2.4) |
| > 5 years | 12 (5.8) |
| No cancer treatment | 48 (23.2) |
* NED: No Evidence of Disease
Diagnosis after surgical oncologic emergency consultation and 30 day follow up for surgical interventions, mortality, and discussion in a multidisciplinary cancer conference (MCC) within the follow up period.
| Classification | N | Diagnose | N | Surgery | Deceased | MCC | |
|---|---|---|---|---|---|---|---|
|
| 86 |
|
|
|
|
| |
| Colorectal | 22 | 16 (72.7) | 3 (13.6) | 11 (50.0) | |||
| Biliary | 19 | 7 (36.8) | 1 (5.3) | 6 (31.6) | |||
| Small intestine | 18 | 14 (77.8) | 4 (22.2) | 7 (38.9) | |||
| Airway | 2 | 1 (50.0) | - | 2 (100) | |||
| Gastroesofageal | 1 | - | 1 (100) | - | |||
|
|
|
|
|
| |||
| Colorectal | 8 | 1 (12.5) | - | 1 (12.5) | |||
| Small intestine | 7 | 5 (71.4) | 1 (14.3) | 1 (14.3) | |||
| Radiation enteritis | 4 | 4 (100) | - | 1 (25.0) | |||
| Biliary | 3 | - | - | 1 (33.3) | |||
| Gastroesofageal | 1 | - | - | - | |||
| Urinary | 1 | - | - | - | |||
|
| 67 |
|
|
|
|
| |
| Score 1 or 2 | 6 | - | - | - | |||
| Score 3 or 4 | 17 | 2 (11.7) | - | 5 (29.4) | |||
| Score 5 | 2 | 1 (50.0) | 2 (100) | - | |||
|
|
|
|
|
| |||
|
|
|
|
|
| |||
|
|
|
|
|
| |||
|
|
|
|
|
| |||
|
|
|
|
|
| |||
| Score 1 or 2 | 3 | 1 (33.3) | - | - | |||
| Score 3 | 1 | - | - | - | |||
|
|
|
|
|
| |||
|
|
|
|
|
| |||
|
|
| - |
| - | |||
|
| 19 |
|
|
|
|
| |
|
|
|
|
|
| |||
|
|
|
|
|
| |||
|
| 12 |
|
|
|
|
| |
|
|
|
|
|
| |||
|
| 12 |
|
|
|
|
| |
|
|
|
|
|
| |||
|
|
|
|
|
| |||
|
| 5 |
|
|
|
|
| |
|
| 6 |
|
|
|
|
| |
|
|
|
|
|
| |||
|
|
|
|
|
| |||
* MCC: Multidisciplinary Cancer Conference
** According to the Southampton Wound Assesment Scale
*** NED: No Evidence of Disease
Fig 1The timing of surgery in relation to the timing of the Multidisciplinary Cancer Conference (MCC).
The MCC is set as timepoint 0.
Fig 2The 30-day clinical pathway of cancer patients after surgical oncologic emergency consultation.
Starting at stage of treatment prior to the consultation, whether patients undergo surgery and/or are being discussed in a *Multidisciplinary Cancer Conference (MCC), and stage of treatment 30 days after surgical oncologic emergency consultation.